Look up one drug

Ontario coverage, price, criteria word for word, Health Canada status and shortages for one product

Patient plan: look up a medication list

Showing products 1–24 of 79. More products

Listed in the December 27, 2023 extract; not in the current extract (Aug 26, 2026): PMS-Ramipril Cap (02247917), PMS-Ramipril Cap (02247918), PMS-Ramipril Cap (02247919). Source: odb-formulary-ed43-extract-2023-12-27.xml; compared with odb-formulary-ed43-extract-2026-08-26.xml.

RAMIPRIL

23 general benefit · 1 not a benefit

Other products in the same Health Canada class (C09AA) — coverage varies; not interchangeable

  • Benazepril (Lotensin): general benefit, Not a benefit
  • Captopril (Noyada): general benefit, Limited Use 707, 723, Not a benefit
  • Cilazapril (Inhibace): general benefit, Not a benefit
  • Enalapril (Vasotec): general benefit, Not a benefit
  • Fosinopril (Monopril): general benefit, Not a benefit
  • Lisinopril (Prinivil): general benefit, Not a benefit

3 more in the class list below

Altace Cap · DIN 02221829 · 1.25mg ·

General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Altace Cap · DIN 02221829 Manufacturer: Sanofi Aventis Pharma; listing date 1999-01-06 Health Canada: Marketed since 2021-01-11 · brand ALTACE · ATC C09AA05 RAMIPRIL · form Capsule · route Oral · ingredients RAMIPRIL 1.25 MG · company Bausch health, canada inc. · schedule Prescription
Check this DIN again · Health Canada product record

Ministry pays: $0.0708 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=43308 · Verify on the e-Formulary ↗ (DIN 02221829)

Source record
DIN 02221829: Altace Cap Raw flags: chronicUseMed=Y, sec3=Y Item: 240800203; group id 350; item number 0802; lccId None; manufacturer id SAV Source form: None; strength: 1.25mg Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): $1.0027; ministry $0.0708 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02221829 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=43308
Interchangeable products
Apo-Ramipril Cap · DIN 02251515 · $0.0708 Auro-Ramipril Cap · DIN 02387387 · $0.0708 Co Ramipril Cap · DIN 02295482 · $0.0708 Jamp-Ramipril Cap · DIN 02331101 · $0.0708 Mar-Ramipril Cap · DIN 02420457 · $0.0708 PMS-Ramipril Cap · DIN 02295369 · $0.0708 PMSC-Ramipril Cap · DIN 02550202 · $0.0708 Pharma-Ramipril · DIN 02469057 · $0.0708 Ramipril Cap · DIN 02299372 · not recorded Ramipril Cap · DIN 02308363 · $0.0708 Ran-Ramipril Cap · DIN 02310503 · $0.0708
Shortage status: resolved shortage (ended 2020-02-10); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02221829
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Apo-Ramipril Cap · DIN 02251515 · 1.25mg ·

General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Apo-Ramipril Cap · DIN 02251515 Manufacturer: Apotex Inc.; listing date 2007-03-09 Health Canada: Marketed since 2006-12-12 · brand APO-RAMIPRIL · ATC C09AA05 RAMIPRIL · form Capsule · route Oral · ingredients RAMIPRIL 1.25 MG · company Apotex inc · schedule Prescription
Check this DIN again · Health Canada product record

Apo-Ramipril Cap: Formulary list price $0.0708/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.0708 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=73644 · Verify on the e-Formulary ↗ (DIN 02251515)

Source record
DIN 02251515: Apo-Ramipril Cap Raw flags: chronicUseMed=Y, sec3=Y Item: 240800203; group id 350; item number 0802; lccId None; manufacturer id APX Source form: None; strength: 1.25mg Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): $0.0708; ministry $0.0708 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02251515 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=73644
Interchangeable products
Altace Cap · DIN 02221829 · $0.0708 Auro-Ramipril Cap · DIN 02387387 · $0.0708 Co Ramipril Cap · DIN 02295482 · $0.0708 Jamp-Ramipril Cap · DIN 02331101 · $0.0708 Mar-Ramipril Cap · DIN 02420457 · $0.0708 PMS-Ramipril Cap · DIN 02295369 · $0.0708 PMSC-Ramipril Cap · DIN 02550202 · $0.0708 Pharma-Ramipril · DIN 02469057 · $0.0708 Ramipril Cap · DIN 02299372 · not recorded Ramipril Cap · DIN 02308363 · $0.0708 Ran-Ramipril Cap · DIN 02310503 · $0.0708
Shortage status: resolved shortage (ended 2024-02-29); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02251515
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Auro-Ramipril Cap · DIN 02387387 · 1.25mg ·

General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Auro-Ramipril Cap · DIN 02387387 Manufacturer: Auro Pharma Inc.; listing date 2013-02-28 Health Canada: Marketed since 2012-09-13 · brand AURO-RAMIPRIL · ATC C09AA05 RAMIPRIL · form Capsule · route Oral · ingredients RAMIPRIL 1.25 MG · company Auro pharma inc · schedule Prescription
Check this DIN again · Health Canada product record

Auro-Ramipril Cap: Formulary list price $0.0708/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.0708 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=87297 · Verify on the e-Formulary ↗ (DIN 02387387)

Source record
DIN 02387387: Auro-Ramipril Cap Raw flags: chronicUseMed=Y, sec3=Y Item: 240800203; group id 350; item number 0802; lccId None; manufacturer id AUR Source form: None; strength: 1.25mg Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): $0.0708; ministry $0.0708 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02387387 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=87297
Interchangeable products
Altace Cap · DIN 02221829 · $0.0708 Apo-Ramipril Cap · DIN 02251515 · $0.0708 Co Ramipril Cap · DIN 02295482 · $0.0708 Jamp-Ramipril Cap · DIN 02331101 · $0.0708 Mar-Ramipril Cap · DIN 02420457 · $0.0708 PMS-Ramipril Cap · DIN 02295369 · $0.0708 PMSC-Ramipril Cap · DIN 02550202 · $0.0708 Pharma-Ramipril · DIN 02469057 · $0.0708 Ramipril Cap · DIN 02299372 · not recorded Ramipril Cap · DIN 02308363 · $0.0708 Ran-Ramipril Cap · DIN 02310503 · $0.0708
Shortage status: resolved shortage (ended 2025-03-17); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02387387
Shortage record checked 2026-09-13T08:10:21.292534+00:00

PMSC-Ramipril Cap · DIN 02550202 · 1.25mg ·

General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
PMSC-Ramipril Cap · DIN 02550202 Manufacturer: Pharmascience Inc.; listing date 2025-12-30 Health Canada: Marketed since 2025-10-03 · brand PMSC-RAMIPRIL · ATC C09AA05 RAMIPRIL · form Capsule · route Oral · ingredients RAMIPRIL 1.25 MG · company Pharmascience inc · schedule Prescription
Check this DIN again · Health Canada product record

PMSC-Ramipril Cap: Formulary list price $0.0708/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.0708 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=103904 · Verify on the e-Formulary ↗ (DIN 02550202)

Source record
DIN 02550202: PMSC-Ramipril Cap Raw flags: chronicUseMed=Y, sec3=Y Item: 240800203; group id 350; item number 0802; lccId None; manufacturer id PMS Source form: None; strength: 1.25mg Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): $0.0708; ministry $0.0708 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02550202 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=103904
Interchangeable products
Altace Cap · DIN 02221829 · $0.0708 Apo-Ramipril Cap · DIN 02251515 · $0.0708 Auro-Ramipril Cap · DIN 02387387 · $0.0708 Co Ramipril Cap · DIN 02295482 · $0.0708 Jamp-Ramipril Cap · DIN 02331101 · $0.0708 Mar-Ramipril Cap · DIN 02420457 · $0.0708 PMS-Ramipril Cap · DIN 02295369 · $0.0708 Pharma-Ramipril · DIN 02469057 · $0.0708 Ramipril Cap · DIN 02299372 · not recorded Ramipril Cap · DIN 02308363 · $0.0708 Ran-Ramipril Cap · DIN 02310503 · $0.0708
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02550202
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Pharma-Ramipril · DIN 02469057 · 1.25mg ·

General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Pharma-Ramipril · DIN 02469057 Manufacturer: Pharmascience Inc.; listing date 2018-09-27 Health Canada: Marketed since 2018-04-16 · brand PHARMA-RAMIPRIL · ATC C09AA05 RAMIPRIL · form Capsule · route Oral · ingredients RAMIPRIL 1.25 MG · company Pharmascience inc · schedule Prescription
Check this DIN again · Health Canada product record

Pharma-Ramipril: Formulary list price $0.0708/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.0708 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=95770 · Verify on the e-Formulary ↗ (DIN 02469057)

Source record
DIN 02469057: Pharma-Ramipril Raw flags: chronicUseMed=Y, sec3=Y Item: 240800203; group id 350; item number 0802; lccId None; manufacturer id PMS Source form: None; strength: 1.25mg Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): $0.0708; ministry $0.0708 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02469057 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=95770
Interchangeable products
Altace Cap · DIN 02221829 · $0.0708 Apo-Ramipril Cap · DIN 02251515 · $0.0708 Auro-Ramipril Cap · DIN 02387387 · $0.0708 Co Ramipril Cap · DIN 02295482 · $0.0708 Jamp-Ramipril Cap · DIN 02331101 · $0.0708 Mar-Ramipril Cap · DIN 02420457 · $0.0708 PMS-Ramipril Cap · DIN 02295369 · $0.0708 PMSC-Ramipril Cap · DIN 02550202 · $0.0708 Ramipril Cap · DIN 02299372 · not recorded Ramipril Cap · DIN 02308363 · $0.0708 Ran-Ramipril Cap · DIN 02310503 · $0.0708
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02469057
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Ramipril Cap · DIN 02308363 · 1.25mg ·

General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Ramipril Cap · DIN 02308363 Manufacturer: Sivem Pharmaceuticals ULC; listing date 2010-06-14 Health Canada: Marketed since 2018-04-26 · brand RAMIPRIL · ATC C09AA05 RAMIPRIL · form Capsule · route Oral · ingredients RAMIPRIL 1.25 MG · company Sivem pharmaceuticals ulc · schedule Prescription
Check this DIN again · Health Canada product record

Ramipril Cap: Formulary list price $0.0708/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.0708 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=79402 · Verify on the e-Formulary ↗ (DIN 02308363)

Source record
DIN 02308363: Ramipril Cap Raw flags: chronicUseMed=Y, sec3=Y Item: 240800203; group id 350; item number 0802; lccId None; manufacturer id SIV Source form: None; strength: 1.25mg Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): $0.0708; ministry $0.0708 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02308363 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=79402
Interchangeable products
Altace Cap · DIN 02221829 · $0.0708 Apo-Ramipril Cap · DIN 02251515 · $0.0708 Auro-Ramipril Cap · DIN 02387387 · $0.0708 Co Ramipril Cap · DIN 02295482 · $0.0708 Jamp-Ramipril Cap · DIN 02331101 · $0.0708 Mar-Ramipril Cap · DIN 02420457 · $0.0708 PMS-Ramipril Cap · DIN 02295369 · $0.0708 PMSC-Ramipril Cap · DIN 02550202 · $0.0708 Pharma-Ramipril · DIN 02469057 · $0.0708 Ramipril Cap · DIN 02299372 · not recorded Ran-Ramipril Cap · DIN 02310503 · $0.0708
Shortage status: resolved shortage (ended 2018-12-30); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02308363
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Ran-Ramipril Cap · DIN 02310503 · 1.25mg ·

General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Ran-Ramipril Cap · DIN 02310503 Manufacturer: Ranbaxy Pharmaceuticals Canada Inc.; listing date 2008-11-04 Health Canada: Marketed since 2020-02-10 · brand TARO-RAMIPRIL · ATC C09AA05 RAMIPRIL · form Capsule · route Oral · ingredients RAMIPRIL 1.25 MG · company Sun pharma canada inc · schedule Prescription
Check this DIN again · Health Canada product record

Ran-Ramipril Cap: Formulary list price $0.0708/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.0708 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=79613 · Verify on the e-Formulary ↗ (DIN 02310503)

Source record
DIN 02310503: Ran-Ramipril Cap Raw flags: chronicUseMed=Y, sec3=Y Item: 240800203; group id 350; item number 0802; lccId None; manufacturer id RAN Source form: None; strength: 1.25mg Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): $0.0708; ministry $0.0708 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02310503 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=79613
Interchangeable products
Altace Cap · DIN 02221829 · $0.0708 Apo-Ramipril Cap · DIN 02251515 · $0.0708 Auro-Ramipril Cap · DIN 02387387 · $0.0708 Co Ramipril Cap · DIN 02295482 · $0.0708 Jamp-Ramipril Cap · DIN 02331101 · $0.0708 Mar-Ramipril Cap · DIN 02420457 · $0.0708 PMS-Ramipril Cap · DIN 02295369 · $0.0708 PMSC-Ramipril Cap · DIN 02550202 · $0.0708 Pharma-Ramipril · DIN 02469057 · $0.0708 Ramipril Cap · DIN 02299372 · not recorded Ramipril Cap · DIN 02308363 · $0.0708
Shortage status: resolved shortage (ended 2026-01-22); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02310503
Shortage record checked 2026-09-13T08:10:21.292534+00:00

AG-Ramipril Cap · DIN 02477572 · 2.5mg ·

General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
AG-Ramipril Cap · DIN 02477572 Manufacturer: Angita Pharma Inc.; listing date 2020-11-30 Health Canada: Marketed since 2018-09-06 · brand AG-RAMIPRIL · ATC C09AA05 RAMIPRIL · form Capsule · route Oral · ingredients RAMIPRIL 2.5 MG · company Angita pharma inc. · schedule Prescription
Check this DIN again · Health Canada product record

AG-Ramipril Cap: Formulary list price $0.0817/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.0817 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=96784 · Verify on the e-Formulary ↗ (DIN 02477572)

Source record
DIN 02477572: AG-Ramipril Cap Raw flags: chronicUseMed=Y, sec3=Y Item: 240800204; group id 350; item number 0803; lccId None; manufacturer id ANG Source form: None; strength: 2.5mg Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): $0.0817; ministry $0.0817 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02477572 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=96784
Interchangeable products
Altace Cap · DIN 02221837 · $0.0817 Apo-Ramipril Cap · DIN 02251531 · $0.0817 Auro-Ramipril Cap · DIN 02387395 · $0.0817 Co Ramipril Cap · DIN 02295490 · $0.0817 Jamp-Ramipril Cap · DIN 02331128 · $0.0817 Mar-Ramipril Cap · DIN 02420465 · $0.0817 Mint-Ramipril Cap · DIN 02421305 · $0.0817 NRA-Ramipril Cap · DIN 02486172 · $0.0817 PMSC-Ramipril Cap · DIN 02550210 · $0.0817 Pharma-Ramipril · DIN 02469065 · $0.0817 Ramipril Cap · DIN 02255316 · not recorded Ramipril Cap · DIN 02287927 · $0.0817 Ramipril Cap · DIN 02374846 · $0.0817 Ran-Ramipril Cap · DIN 02310511 · $0.0817 Ratio-Ramipril Cap · DIN 02287706 · $0.0817 Teva-Ramipril Cap · DIN 02247945 · $0.0817
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02477572
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Altace Cap · DIN 02221837 · 2.5mg ·

General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Altace Cap · DIN 02221837 Manufacturer: Sanofi Aventis Pharma; listing date 1999-01-06 Health Canada: Marketed since 2021-01-11 · brand ALTACE · ATC C09AA05 RAMIPRIL · form Capsule · route Oral · ingredients RAMIPRIL 2.5 MG · company Bausch health, canada inc. · schedule Prescription
Check this DIN again · Health Canada product record

Ministry pays: $0.0817 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=43309 · Verify on the e-Formulary ↗ (DIN 02221837)

Source record
DIN 02221837: Altace Cap Raw flags: chronicUseMed=Y, sec3=Y Item: 240800204; group id 350; item number 0803; lccId None; manufacturer id SAV Source form: None; strength: 2.5mg Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): $1.1281; ministry $0.0817 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02221837 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=43309
Interchangeable products
AG-Ramipril Cap · DIN 02477572 · $0.0817 Apo-Ramipril Cap · DIN 02251531 · $0.0817 Auro-Ramipril Cap · DIN 02387395 · $0.0817 Co Ramipril Cap · DIN 02295490 · $0.0817 Jamp-Ramipril Cap · DIN 02331128 · $0.0817 Mar-Ramipril Cap · DIN 02420465 · $0.0817 Mint-Ramipril Cap · DIN 02421305 · $0.0817 NRA-Ramipril Cap · DIN 02486172 · $0.0817 PMSC-Ramipril Cap · DIN 02550210 · $0.0817 Pharma-Ramipril · DIN 02469065 · $0.0817 Ramipril Cap · DIN 02255316 · not recorded Ramipril Cap · DIN 02287927 · $0.0817 Ramipril Cap · DIN 02374846 · $0.0817 Ran-Ramipril Cap · DIN 02310511 · $0.0817 Ratio-Ramipril Cap · DIN 02287706 · $0.0817 Teva-Ramipril Cap · DIN 02247945 · $0.0817
Shortage status: resolved shortage (ended 2019-10-07); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02221837
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Apo-Ramipril Cap · DIN 02251531 · 2.5mg ·

General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Apo-Ramipril Cap · DIN 02251531 Manufacturer: Apotex Inc.; listing date 2007-03-09 Health Canada: Marketed since 2006-12-12 · brand APO-RAMIPRIL · ATC C09AA05 RAMIPRIL · form Capsule · route Oral · ingredients RAMIPRIL 2.5 MG · company Apotex inc · schedule Prescription
Check this DIN again · Health Canada product record

Apo-Ramipril Cap: Formulary list price $0.0817/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.0817 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=73646 · Verify on the e-Formulary ↗ (DIN 02251531)

Source record
DIN 02251531: Apo-Ramipril Cap Raw flags: chronicUseMed=Y, sec3=Y Item: 240800204; group id 350; item number 0803; lccId None; manufacturer id APX Source form: None; strength: 2.5mg Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): $0.0817; ministry $0.0817 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02251531 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=73646
Interchangeable products
AG-Ramipril Cap · DIN 02477572 · $0.0817 Altace Cap · DIN 02221837 · $0.0817 Auro-Ramipril Cap · DIN 02387395 · $0.0817 Co Ramipril Cap · DIN 02295490 · $0.0817 Jamp-Ramipril Cap · DIN 02331128 · $0.0817 Mar-Ramipril Cap · DIN 02420465 · $0.0817 Mint-Ramipril Cap · DIN 02421305 · $0.0817 NRA-Ramipril Cap · DIN 02486172 · $0.0817 PMSC-Ramipril Cap · DIN 02550210 · $0.0817 Pharma-Ramipril · DIN 02469065 · $0.0817 Ramipril Cap · DIN 02255316 · not recorded Ramipril Cap · DIN 02287927 · $0.0817 Ramipril Cap · DIN 02374846 · $0.0817 Ran-Ramipril Cap · DIN 02310511 · $0.0817 Ratio-Ramipril Cap · DIN 02287706 · $0.0817 Teva-Ramipril Cap · DIN 02247945 · $0.0817
Shortage status: active shortage (reported 2026-06-16, estimated to end 2026-10-02, last updated 2026-09-11); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02251531
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Auro-Ramipril Cap · DIN 02387395 · 2.5mg ·

General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Auro-Ramipril Cap · DIN 02387395 Manufacturer: Auro Pharma Inc.; listing date 2013-02-28 Health Canada: Marketed since 2012-09-13 · brand AURO-RAMIPRIL · ATC C09AA05 RAMIPRIL · form Capsule · route Oral · ingredients RAMIPRIL 2.5 MG · company Auro pharma inc · schedule Prescription
Check this DIN again · Health Canada product record

Auro-Ramipril Cap: Formulary list price $0.0817/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.0817 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=87298 · Verify on the e-Formulary ↗ (DIN 02387395)

Source record
DIN 02387395: Auro-Ramipril Cap Raw flags: chronicUseMed=Y, sec3=Y Item: 240800204; group id 350; item number 0803; lccId None; manufacturer id AUR Source form: None; strength: 2.5mg Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): $0.0817; ministry $0.0817 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02387395 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=87298
Interchangeable products
AG-Ramipril Cap · DIN 02477572 · $0.0817 Altace Cap · DIN 02221837 · $0.0817 Apo-Ramipril Cap · DIN 02251531 · $0.0817 Co Ramipril Cap · DIN 02295490 · $0.0817 Jamp-Ramipril Cap · DIN 02331128 · $0.0817 Mar-Ramipril Cap · DIN 02420465 · $0.0817 Mint-Ramipril Cap · DIN 02421305 · $0.0817 NRA-Ramipril Cap · DIN 02486172 · $0.0817 PMSC-Ramipril Cap · DIN 02550210 · $0.0817 Pharma-Ramipril · DIN 02469065 · $0.0817 Ramipril Cap · DIN 02255316 · not recorded Ramipril Cap · DIN 02287927 · $0.0817 Ramipril Cap · DIN 02374846 · $0.0817 Ran-Ramipril Cap · DIN 02310511 · $0.0817 Ratio-Ramipril Cap · DIN 02287706 · $0.0817 Teva-Ramipril Cap · DIN 02247945 · $0.0817
Shortage status: resolved shortage (ended 2023-12-13); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02387395
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Jamp-Ramipril Cap · DIN 02331128 · 2.5mg ·

General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Jamp-Ramipril Cap · DIN 02331128 Manufacturer: Jamp Pharma Corporation; listing date 2010-04-23 Health Canada: Marketed since 2026-09-01 · brand JAMP RAMIPRIL · ATC C09AA05 RAMIPRIL · form Capsule · route Oral · ingredients RAMIPRIL 2.5 MG · company Jamp pharma corporation · schedule Prescription
Check this DIN again · Health Canada product record

Jamp-Ramipril Cap: Formulary list price $0.0817/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.0817 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=81684 · Verify on the e-Formulary ↗ (DIN 02331128)

Source record
DIN 02331128: Jamp-Ramipril Cap Raw flags: chronicUseMed=Y, sec3=Y Item: 240800204; group id 350; item number 0803; lccId None; manufacturer id JPC Source form: None; strength: 2.5mg Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): $0.0817; ministry $0.0817 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02331128 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=81684
Interchangeable products
AG-Ramipril Cap · DIN 02477572 · $0.0817 Altace Cap · DIN 02221837 · $0.0817 Apo-Ramipril Cap · DIN 02251531 · $0.0817 Auro-Ramipril Cap · DIN 02387395 · $0.0817 Co Ramipril Cap · DIN 02295490 · $0.0817 Mar-Ramipril Cap · DIN 02420465 · $0.0817 Mint-Ramipril Cap · DIN 02421305 · $0.0817 NRA-Ramipril Cap · DIN 02486172 · $0.0817 PMSC-Ramipril Cap · DIN 02550210 · $0.0817 Pharma-Ramipril · DIN 02469065 · $0.0817 Ramipril Cap · DIN 02255316 · not recorded Ramipril Cap · DIN 02287927 · $0.0817 Ramipril Cap · DIN 02374846 · $0.0817 Ran-Ramipril Cap · DIN 02310511 · $0.0817 Ratio-Ramipril Cap · DIN 02287706 · $0.0817 Teva-Ramipril Cap · DIN 02247945 · $0.0817
Shortage status: resolved shortage (ended 2017-11-08); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02331128
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Mar-Ramipril Cap · DIN 02420465 · 2.5mg ·

General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Mar-Ramipril Cap · DIN 02420465 Manufacturer: Marcan Pharmaceuticals Inc.; listing date 2014-05-29 Health Canada: Marketed since 2015-01-09 · brand MAR-RAMIPRIL · ATC C09AA05 RAMIPRIL · form Capsule · route Oral · ingredients RAMIPRIL 2.5 MG · company Marcan pharmaceuticals inc · schedule Prescription
Check this DIN again · Health Canada product record

Mar-Ramipril Cap: Formulary list price $0.0817/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.0817 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=90505 · Verify on the e-Formulary ↗ (DIN 02420465)

Source record
DIN 02420465: Mar-Ramipril Cap Raw flags: chronicUseMed=Y, sec3=Y Item: 240800204; group id 350; item number 0803; lccId None; manufacturer id MAR Source form: None; strength: 2.5mg Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): $0.0817; ministry $0.0817 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02420465 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=90505
Interchangeable products
AG-Ramipril Cap · DIN 02477572 · $0.0817 Altace Cap · DIN 02221837 · $0.0817 Apo-Ramipril Cap · DIN 02251531 · $0.0817 Auro-Ramipril Cap · DIN 02387395 · $0.0817 Co Ramipril Cap · DIN 02295490 · $0.0817 Jamp-Ramipril Cap · DIN 02331128 · $0.0817 Mint-Ramipril Cap · DIN 02421305 · $0.0817 NRA-Ramipril Cap · DIN 02486172 · $0.0817 PMSC-Ramipril Cap · DIN 02550210 · $0.0817 Pharma-Ramipril · DIN 02469065 · $0.0817 Ramipril Cap · DIN 02255316 · not recorded Ramipril Cap · DIN 02287927 · $0.0817 Ramipril Cap · DIN 02374846 · $0.0817 Ran-Ramipril Cap · DIN 02310511 · $0.0817 Ratio-Ramipril Cap · DIN 02287706 · $0.0817 Teva-Ramipril Cap · DIN 02247945 · $0.0817
Shortage status: resolved shortage (ended 2019-07-31); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02420465
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Mint-Ramipril Cap · DIN 02421305 · 2.5mg ·

General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Mint-Ramipril Cap · DIN 02421305 Manufacturer: Mint Pharmaceuticals Inc.; listing date 2014-06-26 Health Canada: Marketed since 2014-03-17 · brand MINT-RAMIPRIL · ATC C09AA05 RAMIPRIL · form Capsule · route Oral · ingredients RAMIPRIL 2.5 MG · company Mint pharmaceuticals inc · schedule Prescription
Check this DIN again · Health Canada product record

Mint-Ramipril Cap: Formulary list price $0.0817/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.0817 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=90594 · Verify on the e-Formulary ↗ (DIN 02421305)

Source record
DIN 02421305: Mint-Ramipril Cap Raw flags: chronicUseMed=Y, sec3=Y Item: 240800204; group id 350; item number 0803; lccId None; manufacturer id MIN Source form: None; strength: 2.5mg Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): $0.0817; ministry $0.0817 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02421305 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=90594
Interchangeable products
AG-Ramipril Cap · DIN 02477572 · $0.0817 Altace Cap · DIN 02221837 · $0.0817 Apo-Ramipril Cap · DIN 02251531 · $0.0817 Auro-Ramipril Cap · DIN 02387395 · $0.0817 Co Ramipril Cap · DIN 02295490 · $0.0817 Jamp-Ramipril Cap · DIN 02331128 · $0.0817 Mar-Ramipril Cap · DIN 02420465 · $0.0817 NRA-Ramipril Cap · DIN 02486172 · $0.0817 PMSC-Ramipril Cap · DIN 02550210 · $0.0817 Pharma-Ramipril · DIN 02469065 · $0.0817 Ramipril Cap · DIN 02255316 · not recorded Ramipril Cap · DIN 02287927 · $0.0817 Ramipril Cap · DIN 02374846 · $0.0817 Ran-Ramipril Cap · DIN 02310511 · $0.0817 Ratio-Ramipril Cap · DIN 02287706 · $0.0817 Teva-Ramipril Cap · DIN 02247945 · $0.0817
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02421305
Shortage record checked 2026-09-13T08:10:21.292534+00:00

NRA-Ramipril Cap · DIN 02486172 · 2.5mg ·

General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
NRA-Ramipril Cap · DIN 02486172 Manufacturer: Nora Pharma; listing date 2020-09-30 Health Canada: Marketed since 2019-09-20 · brand NRA-RAMIPRIL · ATC C09AA05 RAMIPRIL · form Capsule · route Oral · ingredients RAMIPRIL 2.5 MG · company Nora pharma inc · schedule Prescription
Check this DIN again · Health Canada product record

NRA-Ramipril Cap: Formulary list price $0.0817/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.0817 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=97640 · Verify on the e-Formulary ↗ (DIN 02486172)

Source record
DIN 02486172: NRA-Ramipril Cap Raw flags: chronicUseMed=Y, sec3=Y Item: 240800204; group id 350; item number 0803; lccId None; manufacturer id NRA Source form: None; strength: 2.5mg Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): $0.0817; ministry $0.0817 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02486172 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=97640
Interchangeable products
AG-Ramipril Cap · DIN 02477572 · $0.0817 Altace Cap · DIN 02221837 · $0.0817 Apo-Ramipril Cap · DIN 02251531 · $0.0817 Auro-Ramipril Cap · DIN 02387395 · $0.0817 Co Ramipril Cap · DIN 02295490 · $0.0817 Jamp-Ramipril Cap · DIN 02331128 · $0.0817 Mar-Ramipril Cap · DIN 02420465 · $0.0817 Mint-Ramipril Cap · DIN 02421305 · $0.0817 PMSC-Ramipril Cap · DIN 02550210 · $0.0817 Pharma-Ramipril · DIN 02469065 · $0.0817 Ramipril Cap · DIN 02255316 · not recorded Ramipril Cap · DIN 02287927 · $0.0817 Ramipril Cap · DIN 02374846 · $0.0817 Ran-Ramipril Cap · DIN 02310511 · $0.0817 Ratio-Ramipril Cap · DIN 02287706 · $0.0817 Teva-Ramipril Cap · DIN 02247945 · $0.0817
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02486172
Shortage record checked 2026-09-13T08:10:21.292534+00:00

PMSC-Ramipril Cap · DIN 02550210 · 2.5mg ·

General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
PMSC-Ramipril Cap · DIN 02550210 Manufacturer: Pharmascience Inc.; listing date 2025-12-30 Health Canada: Marketed since 2025-10-03 · brand PMSC-RAMIPRIL · ATC C09AA05 RAMIPRIL · form Capsule · route Oral · ingredients RAMIPRIL 2.5 MG · company Pharmascience inc · schedule Prescription
Check this DIN again · Health Canada product record

PMSC-Ramipril Cap: Formulary list price $0.0817/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.0817 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=103905 · Verify on the e-Formulary ↗ (DIN 02550210)

Source record
DIN 02550210: PMSC-Ramipril Cap Raw flags: chronicUseMed=Y, sec3=Y Item: 240800204; group id 350; item number 0803; lccId None; manufacturer id PMS Source form: None; strength: 2.5mg Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): $0.0817; ministry $0.0817 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02550210 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=103905
Interchangeable products
AG-Ramipril Cap · DIN 02477572 · $0.0817 Altace Cap · DIN 02221837 · $0.0817 Apo-Ramipril Cap · DIN 02251531 · $0.0817 Auro-Ramipril Cap · DIN 02387395 · $0.0817 Co Ramipril Cap · DIN 02295490 · $0.0817 Jamp-Ramipril Cap · DIN 02331128 · $0.0817 Mar-Ramipril Cap · DIN 02420465 · $0.0817 Mint-Ramipril Cap · DIN 02421305 · $0.0817 NRA-Ramipril Cap · DIN 02486172 · $0.0817 Pharma-Ramipril · DIN 02469065 · $0.0817 Ramipril Cap · DIN 02255316 · not recorded Ramipril Cap · DIN 02287927 · $0.0817 Ramipril Cap · DIN 02374846 · $0.0817 Ran-Ramipril Cap · DIN 02310511 · $0.0817 Ratio-Ramipril Cap · DIN 02287706 · $0.0817 Teva-Ramipril Cap · DIN 02247945 · $0.0817
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02550210
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Pharma-Ramipril · DIN 02469065 · 2.5mg ·

General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Pharma-Ramipril · DIN 02469065 Manufacturer: Pharmascience Inc.; listing date 2018-09-27 Health Canada: Marketed since 2018-04-16 · brand PHARMA-RAMIPRIL · ATC C09AA05 RAMIPRIL · form Capsule · route Oral · ingredients RAMIPRIL 2.5 MG · company Pharmascience inc · schedule Prescription
Check this DIN again · Health Canada product record

Pharma-Ramipril: Formulary list price $0.0817/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.0817 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=95771 · Verify on the e-Formulary ↗ (DIN 02469065)

Source record
DIN 02469065: Pharma-Ramipril Raw flags: chronicUseMed=Y, sec3=Y Item: 240800204; group id 350; item number 0803; lccId None; manufacturer id PMS Source form: None; strength: 2.5mg Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): $0.0817; ministry $0.0817 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02469065 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=95771
Interchangeable products
AG-Ramipril Cap · DIN 02477572 · $0.0817 Altace Cap · DIN 02221837 · $0.0817 Apo-Ramipril Cap · DIN 02251531 · $0.0817 Auro-Ramipril Cap · DIN 02387395 · $0.0817 Co Ramipril Cap · DIN 02295490 · $0.0817 Jamp-Ramipril Cap · DIN 02331128 · $0.0817 Mar-Ramipril Cap · DIN 02420465 · $0.0817 Mint-Ramipril Cap · DIN 02421305 · $0.0817 NRA-Ramipril Cap · DIN 02486172 · $0.0817 PMSC-Ramipril Cap · DIN 02550210 · $0.0817 Ramipril Cap · DIN 02255316 · not recorded Ramipril Cap · DIN 02287927 · $0.0817 Ramipril Cap · DIN 02374846 · $0.0817 Ran-Ramipril Cap · DIN 02310511 · $0.0817 Ratio-Ramipril Cap · DIN 02287706 · $0.0817 Teva-Ramipril Cap · DIN 02247945 · $0.0817
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02469065
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Ramipril Cap · DIN 02287927 · 2.5mg ·

General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Ramipril Cap · DIN 02287927 Manufacturer: Sivem Pharmaceuticals ULC; listing date 2010-06-14 Health Canada: Marketed since 2018-04-26 · brand RAMIPRIL · ATC C09AA05 RAMIPRIL · form Capsule · route Oral · ingredients RAMIPRIL 2.5 MG · company Sivem pharmaceuticals ulc · schedule Prescription
Check this DIN again · Health Canada product record

Ramipril Cap: Formulary list price $0.0817/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.0817 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=77332 · Verify on the e-Formulary ↗ (DIN 02287927)

Source record
DIN 02287927: Ramipril Cap Raw flags: chronicUseMed=Y, sec3=Y Item: 240800204; group id 350; item number 0803; lccId None; manufacturer id SIV Source form: None; strength: 2.5mg Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): $0.0817; ministry $0.0817 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02287927 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=77332
Interchangeable products
AG-Ramipril Cap · DIN 02477572 · $0.0817 Altace Cap · DIN 02221837 · $0.0817 Apo-Ramipril Cap · DIN 02251531 · $0.0817 Auro-Ramipril Cap · DIN 02387395 · $0.0817 Co Ramipril Cap · DIN 02295490 · $0.0817 Jamp-Ramipril Cap · DIN 02331128 · $0.0817 Mar-Ramipril Cap · DIN 02420465 · $0.0817 Mint-Ramipril Cap · DIN 02421305 · $0.0817 NRA-Ramipril Cap · DIN 02486172 · $0.0817 PMSC-Ramipril Cap · DIN 02550210 · $0.0817 Pharma-Ramipril · DIN 02469065 · $0.0817 Ramipril Cap · DIN 02255316 · not recorded Ramipril Cap · DIN 02374846 · $0.0817 Ran-Ramipril Cap · DIN 02310511 · $0.0817 Ratio-Ramipril Cap · DIN 02287706 · $0.0817 Teva-Ramipril Cap · DIN 02247945 · $0.0817
Shortage status: resolved shortage (ended 2018-07-06); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02287927
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Ran-Ramipril Cap · DIN 02310511 · 2.5mg ·

General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Ran-Ramipril Cap · DIN 02310511 Manufacturer: Ranbaxy Pharmaceuticals Canada Inc.; listing date 2008-11-04 Health Canada: Marketed since 2020-02-10 · brand TARO-RAMIPRIL · ATC C09AA05 RAMIPRIL · form Capsule · route Oral · ingredients RAMIPRIL 2.5 MG · company Sun pharma canada inc · schedule Prescription
Check this DIN again · Health Canada product record

Ran-Ramipril Cap: Formulary list price $0.0817/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.0817 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=79614 · Verify on the e-Formulary ↗ (DIN 02310511)

Source record
DIN 02310511: Ran-Ramipril Cap Raw flags: chronicUseMed=Y, sec3=Y Item: 240800204; group id 350; item number 0803; lccId None; manufacturer id RAN Source form: None; strength: 2.5mg Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): $0.0817; ministry $0.0817 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02310511 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=79614
Interchangeable products
AG-Ramipril Cap · DIN 02477572 · $0.0817 Altace Cap · DIN 02221837 · $0.0817 Apo-Ramipril Cap · DIN 02251531 · $0.0817 Auro-Ramipril Cap · DIN 02387395 · $0.0817 Co Ramipril Cap · DIN 02295490 · $0.0817 Jamp-Ramipril Cap · DIN 02331128 · $0.0817 Mar-Ramipril Cap · DIN 02420465 · $0.0817 Mint-Ramipril Cap · DIN 02421305 · $0.0817 NRA-Ramipril Cap · DIN 02486172 · $0.0817 PMSC-Ramipril Cap · DIN 02550210 · $0.0817 Pharma-Ramipril · DIN 02469065 · $0.0817 Ramipril Cap · DIN 02255316 · not recorded Ramipril Cap · DIN 02287927 · $0.0817 Ramipril Cap · DIN 02374846 · $0.0817 Ratio-Ramipril Cap · DIN 02287706 · $0.0817 Teva-Ramipril Cap · DIN 02247945 · $0.0817
Shortage status: resolved shortage (ended 2026-01-21); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02310511
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Teva-Ramipril Cap · DIN 02247945 · 2.5mg ·

General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Teva-Ramipril Cap · DIN 02247945 Manufacturer: Teva Canada Limited; listing date 2007-06-06 Health Canada: Marketed since 2010-05-27 · brand TEVA-RAMIPRIL · ATC C09AA05 RAMIPRIL · form Capsule · route Oral · ingredients RAMIPRIL 2.5 MG · company Teva canada limited · schedule Prescription
Check this DIN again · Health Canada product record

Teva-Ramipril Cap: Formulary list price $0.0817/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.0817 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=72255 · Verify on the e-Formulary ↗ (DIN 02247945)

Source record
DIN 02247945: Teva-Ramipril Cap Raw flags: chronicUseMed=Y, sec3=Y Item: 240800204; group id 350; item number 0803; lccId None; manufacturer id TEV Source form: None; strength: 2.5mg Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): $0.0817; ministry $0.0817 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02247945 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=72255
Interchangeable products
AG-Ramipril Cap · DIN 02477572 · $0.0817 Altace Cap · DIN 02221837 · $0.0817 Apo-Ramipril Cap · DIN 02251531 · $0.0817 Auro-Ramipril Cap · DIN 02387395 · $0.0817 Co Ramipril Cap · DIN 02295490 · $0.0817 Jamp-Ramipril Cap · DIN 02331128 · $0.0817 Mar-Ramipril Cap · DIN 02420465 · $0.0817 Mint-Ramipril Cap · DIN 02421305 · $0.0817 NRA-Ramipril Cap · DIN 02486172 · $0.0817 PMSC-Ramipril Cap · DIN 02550210 · $0.0817 Pharma-Ramipril · DIN 02469065 · $0.0817 Ramipril Cap · DIN 02255316 · not recorded Ramipril Cap · DIN 02287927 · $0.0817 Ramipril Cap · DIN 02374846 · $0.0817 Ran-Ramipril Cap · DIN 02310511 · $0.0817 Ratio-Ramipril Cap · DIN 02287706 · $0.0817
Shortage status: shortage reported ended 2026-05-05 (report last updated 2026-05-05); confirm supply with the pharmacy; reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02247945
Shortage record checked 2026-09-13T08:10:21.292534+00:00

AG-Ramipril Cap · DIN 02477580 · 5mg ·

General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
AG-Ramipril Cap · DIN 02477580 Manufacturer: Angita Pharma Inc.; listing date 2020-11-30 Health Canada: Marketed since 2018-09-06 · brand AG-RAMIPRIL · ATC C09AA05 RAMIPRIL · form Capsule · route Oral · ingredients RAMIPRIL 5 MG · company Angita pharma inc. · schedule Prescription
Check this DIN again · Health Canada product record

AG-Ramipril Cap: Formulary list price $0.0817/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.0817 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=96785 · Verify on the e-Formulary ↗ (DIN 02477580)

Source record
DIN 02477580: AG-Ramipril Cap Raw flags: chronicUseMed=Y, sec3=Y Item: 240800205; group id 350; item number 0804; lccId None; manufacturer id ANG Source form: None; strength: 5mg Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): $0.0817; ministry $0.0817 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02477580 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=96785
Interchangeable products
Altace Cap · DIN 02221845 · $0.0817 Apo-Ramipril Cap · DIN 02251574 · $0.0817 Auro-Ramipril Cap · DIN 02387409 · $0.0817 Co Ramipril Cap · DIN 02295504 · $0.0817 Jamp-Ramipril Cap · DIN 02331136 · $0.0817 Mar-Ramipril Cap · DIN 02420473 · $0.0817 Mint-Ramipril Cap · DIN 02421313 · $0.0817 NRA-Ramipril Cap · DIN 02486180 · $0.0817 PMSC-Ramipril Cap · DIN 02550229 · $0.0817 Pharma-Ramipril · DIN 02469073 · $0.0817 Ramipril Cap · DIN 02255324 · not recorded Ramipril Cap · DIN 02287935 · $0.0817 Ramipril Cap · DIN 02374854 · $0.0817 Ran-Ramipril Cap · DIN 02310538 · $0.0817 Teva-Ramipril Cap · DIN 02247946 · $0.0817
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02477580
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Altace Cap · DIN 02221845 · 5mg ·

General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Altace Cap · DIN 02221845 Manufacturer: Sanofi Aventis Pharma; listing date 1999-01-06 Health Canada: Marketed since 2021-01-11 · brand ALTACE · ATC C09AA05 RAMIPRIL · form Capsule · route Oral · ingredients RAMIPRIL 5 MG · company Bausch health, canada inc. · schedule Prescription
Check this DIN again · Health Canada product record

Ministry pays: $0.0817 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=43310 · Verify on the e-Formulary ↗ (DIN 02221845)

Source record
DIN 02221845: Altace Cap Raw flags: chronicUseMed=Y, sec3=Y Item: 240800205; group id 350; item number 0804; lccId None; manufacturer id SAV Source form: None; strength: 5mg Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): $1.1575; ministry $0.0817 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02221845 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=43310
Interchangeable products
AG-Ramipril Cap · DIN 02477580 · $0.0817 Apo-Ramipril Cap · DIN 02251574 · $0.0817 Auro-Ramipril Cap · DIN 02387409 · $0.0817 Co Ramipril Cap · DIN 02295504 · $0.0817 Jamp-Ramipril Cap · DIN 02331136 · $0.0817 Mar-Ramipril Cap · DIN 02420473 · $0.0817 Mint-Ramipril Cap · DIN 02421313 · $0.0817 NRA-Ramipril Cap · DIN 02486180 · $0.0817 PMSC-Ramipril Cap · DIN 02550229 · $0.0817 Pharma-Ramipril · DIN 02469073 · $0.0817 Ramipril Cap · DIN 02255324 · not recorded Ramipril Cap · DIN 02287935 · $0.0817 Ramipril Cap · DIN 02374854 · $0.0817 Ran-Ramipril Cap · DIN 02310538 · $0.0817 Teva-Ramipril Cap · DIN 02247946 · $0.0817
Shortage status: resolved shortage (ended 2018-02-15); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02221845
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Apo-Ramipril Cap · DIN 02251574 · 5mg ·

General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Apo-Ramipril Cap · DIN 02251574 Manufacturer: Apotex Inc.; listing date 2007-03-09 Health Canada: Marketed since 2006-12-12 · brand APO-RAMIPRIL · ATC C09AA05 RAMIPRIL · form Capsule · route Oral · ingredients RAMIPRIL 5 MG · company Apotex inc · schedule Prescription
Check this DIN again · Health Canada product record

Apo-Ramipril Cap: Formulary list price $0.0817/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.0817 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=73648 · Verify on the e-Formulary ↗ (DIN 02251574)

Source record
DIN 02251574: Apo-Ramipril Cap Raw flags: chronicUseMed=Y, sec3=Y Item: 240800205; group id 350; item number 0804; lccId None; manufacturer id APX Source form: None; strength: 5mg Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): $0.0817; ministry $0.0817 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02251574 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=73648
Interchangeable products
AG-Ramipril Cap · DIN 02477580 · $0.0817 Altace Cap · DIN 02221845 · $0.0817 Auro-Ramipril Cap · DIN 02387409 · $0.0817 Co Ramipril Cap · DIN 02295504 · $0.0817 Jamp-Ramipril Cap · DIN 02331136 · $0.0817 Mar-Ramipril Cap · DIN 02420473 · $0.0817 Mint-Ramipril Cap · DIN 02421313 · $0.0817 NRA-Ramipril Cap · DIN 02486180 · $0.0817 PMSC-Ramipril Cap · DIN 02550229 · $0.0817 Pharma-Ramipril · DIN 02469073 · $0.0817 Ramipril Cap · DIN 02255324 · not recorded Ramipril Cap · DIN 02287935 · $0.0817 Ramipril Cap · DIN 02374854 · $0.0817 Ran-Ramipril Cap · DIN 02310538 · $0.0817 Teva-Ramipril Cap · DIN 02247946 · $0.0817
Shortage status: resolved shortage (ended 2026-09-10); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02251574
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Ramipril Cap · DIN 02255316 · 2.5mg ·

Listed, not a benefitMarketed · checked 2026-09-02
StatusListed, not a benefit
Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Ramipril Cap · DIN 02255316 Manufacturer: Laboratoire Riva Inc.; listing date 2008-08-28 Health Canada: Marketed since 2017-11-13 · brand RAMIPRIL · ATC C09AA05 RAMIPRIL · form Capsule · route Oral · ingredients RAMIPRIL 2.5 MG · company Laboratoire riva inc. · schedule Prescription
Check this DIN again · Health Canada product record

Ramipril Cap: Formulary list price not recorded/unit (unit not stated in source; not the patient's cost)

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=74047 · Verify on the e-Formulary ↗ (DIN 02255316)

Source record
DIN 02255316: Ramipril Cap Raw flags: chronicUseMed=Y, notABenefit=Y, sec3=Y Item: 240800204; group id 350; item number 0803; lccId None; manufacturer id RIA Source form: None; strength: 2.5mg Recorded listing: Listed, not a benefit; ODB pays only for the benefit products in this interchangeable category; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): not recorded; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02255316 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=74047
Interchangeable products
AG-Ramipril Cap · DIN 02477572 · $0.0817 Altace Cap · DIN 02221837 · $0.0817 Apo-Ramipril Cap · DIN 02251531 · $0.0817 Auro-Ramipril Cap · DIN 02387395 · $0.0817 Co Ramipril Cap · DIN 02295490 · $0.0817 Jamp-Ramipril Cap · DIN 02331128 · $0.0817 Mar-Ramipril Cap · DIN 02420465 · $0.0817 Mint-Ramipril Cap · DIN 02421305 · $0.0817 NRA-Ramipril Cap · DIN 02486172 · $0.0817 PMSC-Ramipril Cap · DIN 02550210 · $0.0817 Pharma-Ramipril · DIN 02469065 · $0.0817 Ramipril Cap · DIN 02287927 · $0.0817 Ramipril Cap · DIN 02374846 · $0.0817 Ran-Ramipril Cap · DIN 02310511 · $0.0817 Ratio-Ramipril Cap · DIN 02287706 · $0.0817 Teva-Ramipril Cap · DIN 02247945 · $0.0817
Shortage status: resolved shortage (ended 2018-06-20); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02255316
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Other drugs in the same formulary class (24:08 Hypotensive Drugs (For Diuretics See 40:28)) and how they are covered

Matched class: 24:08 Hypotensive Drugs (For Diuretics See 40:28)

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Covered without a code on the Ontario formulary: CANDESARTAN CILEXETIL, CANDESARTAN CILEXETIL & HYDROCHLOROTHIAZIDE, CILAZAPRIL & HYDROCHLOROTHIAZIDE, LABETALOL HCL, LOSARTAN POTASSIUM, LOSARTAN POTASSIUM & HYDROCHLOROTHIAZIDE, MINOXIDIL, OLMESARTAN MEDOXOMIL, OLMESARTAN MEDOXOMIL & HYDROCHLOROTHIAZIDE, PERINDOPRIL ERBUMINE, PERINDOPRIL ERBUMINE & INDAPAMIDE, PINDOLOL & HYDROCHLOROTHIAZIDE, TELMISARTAN, TELMISARTAN & AMLODIPINE BESYLATE, TELMISARTAN & HYDROCHLOROTHIAZIDE, VALSARTAN & HYDROCHLOROTHIAZIDE Some products covered without a code (check the product listing): ATENOLOL & CHLORTHALIDONE, BENAZEPRIL, CAPTOPRIL, CILAZAPRIL, CLONIDINE HCL, DOXAZOSIN MESYLATE, ENALAPRIL MALEATE, FELODIPINE, FOSINOPRIL SODIUM, HYDRALAZINE HCL, IRBESARTAN, IRBESARTAN & HYDROCHLOROTHIAZIDE, LISINOPRIL, LISINOPRIL & HYDROCHLOROTHIAZIDE, METHYLDOPA, NIFEDIPINE, PINDOLOL, PRAZOSIN HCL, QUINAPRIL, QUINAPRIL & HYDROCHLOROTHIAZIDE, TERAZOSIN HCL, TRANDOLAPRIL, VALSARTAN, VERAPAMIL HCL 24:08 Hypotensive Drugs (For Diuretics See 40:28)

BENAZEPRIL

· 6 products · Listed, not a benefit (3), General benefit (3) · strengths: 5mg, 10mg, 20mg · Tab

CAPTOPRIL

· 14 products · Limited Use, codes 707, 723 (2), Listed, not a benefit (4), General benefit (8) · strengths: 5mg/5mL, 25mg/5mL, 12.5mg, 25mg, 50mg, 100mg · Oral Sol, Tab

CILAZAPRIL

· 8 products · Listed, not a benefit (2), General benefit (6) · strengths: 1mg, 2.5mg, 5mg · Tab

ENALAPRIL MALEATE

· 52 products · Listed, not a benefit (1), General benefit (51) · strengths: 2.5mg, 5mg, 10mg, 20mg · Tab

FOSINOPRIL SODIUM

· 12 products · Listed, not a benefit (2), General benefit (10) · strengths: 10mg, 20mg · Tab

LISINOPRIL

· 45 products · Listed, not a benefit (1), General benefit (44) · strengths: 5mg, 10mg, 20mg · Tab

PERINDOPRIL ERBUMINE

· 45 products · General benefit · strengths: 2mg, 4mg, 8mg · Tab

QUINAPRIL

· 12 products · Listed, not a benefit (4), General benefit (8) · strengths: 5mg, 10mg, 20mg, 40mg · Tab

TRANDOLAPRIL

· 26 products · Off-Formulary Interchangeable, not an ODB benefit (5), General benefit (21) · strengths: 0.5mg, 1mg, 2mg, 4mg · Cap

ATENOLOL & CHLORTHALIDONE

· 4 products · Listed, not a benefit (2), General benefit (2) · strengths: 50 & 25mg, 100 & 25mg · Tab

CANDESARTAN CILEXETIL

· 59 products · General benefit · strengths: 4mg, 8mg, 16mg, 32mg · Tab

CANDESARTAN CILEXETIL & HYDROCHLOROTHIAZIDE

· 21 products · General benefit · strengths: 16mg & 12.5mg, 32mg & 12.5mg, 32mg & 25mg · Tab Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26; class 24:08 and 34 more
Full class listing Related classes: 24:04 Cardiac Drugs, 24:06 Antilipemic Drugs, 24:12 Vasodilating Drugs, 24:32 Renin-Angiotensin Aldosterone Inhibitors Same formulary class, not same indication: class membership alone does not establish equivalent uses.
Other drugs whose Health Canada label lists a similar indication: hypertension
From Health Canada product monographs; label wording only, not a treatment recommendation. Matching is lexical and uses one held product label per generic; formulations and qualifying criteria may differ. Covered without a code on the Ontario formulary: CANDESARTAN CILEXETIL, CANDESARTAN CILEXETIL & HYDROCHLOROTHIAZIDE, CILAZAPRIL & HYDROCHLOROTHIAZIDE ACEBUTOLOL HCL · Listed, not a benefit (3), General benefit (6) INDICATIONS AND CLINICAL USE APO-ACEBUTOLOL is indicated for the following:  Treatment of mild to moderate hypertension.  Long-term management of patients with angina pectoris due to ischemic heart disease. PM: https://pdf.hres.ca/dpd_pm/00047998.PDF; date October 24, 2018; DIN 02147602; fetched 2026-09-10 Product monograph AMLODIPINE · Limited Use, codes 645, 706 (1), Off-Formulary Interchangeable, not an ODB benefit (11), General benefit (44) 1 INDICATIONS NORVASC (amlodipine besylate tablets) is indicated for: • Hypertension NORVASC is indicated in the treatment of mild to moderate essential hypertension. PM: https://pdf.hres.ca/dpd_pm/00071908.PDF; date AUG 02, 2023; DIN 00878928; fetched 2026-09-10 Product monograph AZILSARTAN MEDOXOMIL · Off-Formulary Interchangeable, not an ODB benefit 1 Part 1: Healthcare Professional Information Indications • EDARBI (azilsartan medoxomil) is an angiotensin II receptor blocker (ARB) indicated for the treatment of mild to moderate essential hypertension. PM: https://pdf.hres.ca/dpd_pm/00082489.PDF; date 2025-10-24; DIN 02381389; fetched 2026-09-10 Product monograph BENAZEPRIL · Listed, not a benefit (3), General benefit (3) Indications BENAZEPRIL (benazepril hydrochloride tablets) is indicated for:  Treatment of mild to moderate essential hypertension. PM: https://pdf.hres.ca/dpd_pm/00080887.PDF; date 2025-06-24; DIN 02273918; fetched 2026-09-10 Product monograph CANDESARTAN CILEXETIL · General benefit • Heart Failure o The treatment of NYHA Class II and III heart failure with ejection fraction ≤ 40% in addition to standard therapy, with or without an ACE inhibitor. 1.1 Pediatrics Pediatrics (6 to 17 years of age): • Hypertension ATACAND is indicated for the treatment of essential hypertension in children and adolescents 6 to 17 years of age (see 7.1.3 Pediatrics, 14 CLINICAL TRIALS). PM: https://pdf.hres.ca/dpd_pm/00085412.PDF; date JUL 17, 2026; DIN 02239090; fetched 2026-09-10 Product monograph • Hypertension PM: https://pdf.hres.ca/dpd_pm/00085412.PDF; date JUL 17, 2026; DIN 02239090; fetched 2026-09-10 Product monograph CANDESARTAN CILEXETIL & HYDROCHLOROTHIAZIDE · General benefit 1 INDICATIONS ATACAND PLUS (candesartan cilexetil/hydrochlorothiazide) is indicated for: • the treatment of essential hypertension in patients for whom combination therapy is appropriate. PM: https://pdf.hres.ca/dpd_pm/00076288.PDF; date JUN 18, 2001; DIN 02244021; fetched 2026-09-10 Product monograph CHLORTHALIDONE · Listed, not a benefit (1), General benefit (2) 1 INDICATIONS APO-CHLORTHALIDONE (chlorthalidone) is indicated for: • Treatment of hypertension. PM: https://pdf.hres.ca/dpd_pm/00069909.PDF; date MAR 14, 2023; DIN 00360279; fetched 2026-09-10 Product monograph CILAZAPRIL & HYDROCHLOROTHIAZIDE · General benefit 1 INDICATIONS INHIBACE PLUS (cilazapril and hydrochlorothiazide) is indicated for:  treatment of mild to moderate essential hypertension in patients for whom combination therapy with both cilazapril and hydrochlorothiazide is appropriate. PM: https://pdf.hres.ca/dpd_pm/00066994.PDF; date September 07, 1995; DIN 02181479; fetched 2026-09-10 Product monograph CLONIDINE HCL · Off-Formulary Interchangeable, not an ODB benefit (7), Listed, not a benefit (2), General benefit (8) INDICATIONS AND CLINICAL USE TEVA-CLONIDINE (clonidine hydrochloride) is indicated for the treatment of hypertension. PM: https://pdf.hres.ca/dpd_pm/00024986.PDF; date April 25, 2014; DIN 02046121; fetched 2026-09-10 Product monograph ENALAPRIL MALEATE & HYDROCHLOROTHIAZIDE · Off-Formulary Interchangeable, not an ODB benefit 1 INDICATIONS VASERETIC® (enalapril and hydrochlorothiazide) is indicated for:  Treatment of essential hypertension in patients for whom this combination therapy with enalapril and hydrochlorothiazide is appropriate. PM: https://pdf.hres.ca/dpd_pm/00068096.PDF; date November 4, 2022; DIN 00657298; fetched 2026-09-10 Product monograph and 20 more Coverage source: ON formulary extract 2026-08-26
What the Health Canada label says it is for
INDICATIONS AND CLINICAL USE ALTACE (ramipril) is indicated for:  Treatment of Essential Hypertension. It may be used alone or in association with thiazide diuretics or with the calcium channel blocker felodipine. The safety and efficacy of ALTACE in renovascular hypertension have not been established and therefore, its use in this condition is not recommended. ALTACE can also be tried as an initial agent in those patients in whom use of diuretics and/or beta blockers are contraindicated or in patients with medical conditions in which these drugs frequently cause serious adverse effects. The safety and efficacy of concurrent use of ALTACE with antihypertensive agents other than thiazide diuretics have not been established.  Treatment Following Acute Myocardial Infarction in clinically stable patients with signs of left ventricular dysfunction to improve survival and reduce hospitalizations for heart failure. Sufficient experience in the treatment of patients with severe (NYHA class IV) heart failure immediately after myocardial infarction is not yet available (see WARNINGS AND PRE… https://pdf.hres.ca/dpd_pm/00059606.PDF PM date: January 8, 2021 Source product: ALTACE; DIN 02221829; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.
What the Health Canada label says it is for
1 INDICATIONS pms-RAMIPRIL-HCTZ (ramipril/hydrochlorothiazide) is indicated for the treatment of essential hypertension in patients for whom this combination therapy is appropriate. pms-RAMIPRIL-HCTZ is not indicated for initial therapy (see 4 DOSAGE AND ADMINISTRATION). Patients in whom ramipril and diuretic are initiated simultaneously can develop symptomatic hypotension. Patients should be titrated on individual drugs. If the fixed combination represents the dose and dosing frequency determined by this titration, the use of pms-RAMIPRIL-HCTZ may be more convenient in the management of patients. If during maintenance therapy dosage adjustment is necessary, it is advisable to use the individual drugs. Pediatrics Pediatrics (< 18 years of age): The safety and effectiveness of ramipril and hydrochlorothiazide in pediatric patients have not been established. Therefore, pms-RAMIPRIL-HCTZ is not indicated in this patient population. Geriatrics Geriatrics (> 65 years of age): There is limited clinical experience with ramipril and hydrochlorothiazide in the elderly (> 65 years) (see 7.1.4 Geriatrics). https://pdf.hres.ca/dpd_pm/00071439.PDF PM date: June 20, 2023 Source product: PMS-RAMIPRIL-HCTZ; DIN 02342154; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.

Availability

Apo-Ramipril Cap · DIN 02251531 Shortage status: active shortage (reported 2026-06-16, estimated to end 2026-10-02, last updated 2026-09-11); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02251531

Check this DIN again

Teva-Ramipril Cap · DIN 02247945 Shortage status: shortage reported ended 2026-05-05 (report last updated 2026-05-05); confirm supply with the pharmacy; reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02247945

Check this DIN again

Other review policies

For Ramipril Cap: no applicable EAP criteria are held and no ODB benefit is established. These policies do not establish coverage.

For rare, immediately life-, limb- or organ-threatening circumstances, the Compassionate Review Policy may consider an unfunded drug or indication, subject to its criteria and without bypassing the drug review process. Compassionate Review Policy

Compassionate Review Policy: source quote
Where there are rare clinical circumstances in immediately life, limb, or organ-threatening conditions, the Executive Officer will also consider requests for drugs or indications in situations where there has not been a decision by the Executive Officer to provide funding of the drug or indication as part of the Ontario Drug Benefit program (and the EAP), and the drug or indication requested would not circumvent the established review process for new drugs or indications as part of the drug submission process for listing within the Ontario Drug Benefit program. Requests must meet the criteria for the Compassionate Review Policy.

Ontario source; updated September 15, 2026

For cancer drugs, Case-by-Case Review considers rare, immediately life-threatening circumstances when no satisfactory funded treatment exists; its criteria and application process apply. Case-by-Case Review (cancer drugs)

Case-by-Case Review (cancer drugs): source quote
Note: Requests for cancer drugs are considered under the Case-by-Case Review Program (CBCRP) which is administered by Ontario Health (Cancer Care Ontario) on behalf of the Ministry of Health. The CBCRP considers funding requests for drugs (both oral therapies and injectable drugs) for the treatment of cancer in patients who have a rare clinical circumstance that is immediately life-threatening (death is likely within a matter of months) and who require treatment with an unfunded drug, because there is no other satisfactory and funded treatment. Please refer to the Ontario Health website for information on the application process, FAQs, eligibility criteria and program policies.

Ontario source; updated September 15, 2026